Millipore Sigma Vibrant Logo

189406 Aurora Kinase/Cdk Inhibitor - CAS 443797-96-4 - Calbiochem

The Aurora Kinase/Cdk Inhibitor, also referenced under CAS 443797-96-4, controls the biological activity of Aurora Kinase/Cdk. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: 4-(5-Amino-1-(2,6-difluorobenzoyl)-1H-[1,2,4]triazol-3-ylamino)-benzenesulfonamide, Aurora Kinase Inhibitor I, JNJ-7706621

Primary Target: Aurora Kinase/Cdk
View Products on Sigmaaldrich.com
189406
View Pricing & Availability

Overview

Replacement Information

Key Spec Table

CAS #Empirical Formula
443797-96-4C₁₅H₁₂F₂N₆O₃S • CH₃CN

Pricing & Availability

Catalogue Number AvailabilityPackaging Qty/Pack Price Quantity
189406-5MG
Retrieving availability...
—
Limited Availability Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      		 Plastic ampoule 5 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      —
      Request Pricing
      		 —
      Description
      OverviewA cell-permeable triazolylsulfonamido compound that acts a reversible, ATP-competitive kinase inhibitor with selectivities towards Aurora kinases (IC50 = 11 and 15 nM for Aurora-A, Aurora-B, respectively) and Cdk's (IC50 = 9, 4, and 3 nM for Cdk1/B, Cdk2/A, and Cdk2/E, respectively). Displays antitumor properties both in vitro (IC50 in the range of 112 - 514 nM against various human cancer cell lines) and in a xenograft murine model in vivo (75-100 mg/kg, i.p.).
      Catalogue Number189406
      Brand Family Calbiochem®
      Synonyms4-(5-Amino-1-(2,6-difluorobenzoyl)-1H-[1,2,4]triazol-3-ylamino)-benzenesulfonamide, Aurora Kinase Inhibitor I, JNJ-7706621
      References
      ReferencesEmanuel, S., et al. 2005. Cancer Res. 65, 9038.
      Lin R., et al. 2005. J. Med. Chem. 48, 4208.
      Product Information
      CAS number443797-96-4
      ATP CompetitiveY
      FormWhite solid
      Hill FormulaC₁₅H₁₂F₂N₆O₃S • CH₃CN
      Chemical formulaC₁₅H₁₂F₂N₆O₃S • CH₃CN
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetAurora Kinase/Cdk
      Primary Target IC<sub>50</sub>11 and 15 nM for Aurora-A, Aurora-B, respectively; 9, 4, and 3 nM for Cdk1/B, Cdk2/A, and Cdk2/E, respectively
      Purity≥97% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Harmful
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      189406-5MG 04055977221756

      Documentation

      Required Licenses

      Title
      PRODUCTO REGULADO POR LA SECRETARÍA DE SALUD

      Aurora Kinase/Cdk Inhibitor - CAS 443797-96-4 - Calbiochem SDS

      Title

      Safety Data Sheet (SDS) 

      Aurora Kinase/Cdk Inhibitor - CAS 443797-96-4 - Calbiochem Certificates of Analysis

      TitleLot Number
      189406

      References

      Reference overview
      Emanuel, S., et al. 2005. Cancer Res. 65, 9038.
      Lin R., et al. 2005. J. Med. Chem. 48, 4208.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision17-April-2008 RFH
      Synonyms4-(5-Amino-1-(2,6-difluorobenzoyl)-1H-[1,2,4]triazol-3-ylamino)-benzenesulfonamide, Aurora Kinase Inhibitor I, JNJ-7706621
      DescriptionA cell-permeable triazolylsulfonamido compound that acts a reversible, ATP-competitive kinase inhibitor with selectivities towards Aurora kinases (IC50 = 11 and 15 nM for Aurora-A, Aurora-B, respectively) and Cdk's (IC50 = 9, 4, and 3 nM for Cdk1/B, Cdk2/A, and Cdk2/E, respectively). Displays antitumor properties both in vitro (IC50 in the range of 112-514 nM against various human cancer cell lines) and in a xenograft murine model in vivo (75-100 mg/kg, i.p.).
      FormWhite solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number443797-96-4
      Chemical formulaC₁₅H₁₂F₂N₆O₃S • CH₃CN
      Structure formulaStructure formula
      Purity≥97% by HPLC
      SolubilityDMSO (15 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
      Toxicity Harmful
      ReferencesEmanuel, S., et al. 2005. Cancer Res. 65, 9038.
      Lin R., et al. 2005. J. Med. Chem. 48, 4208.